 |
|
Failure of Treatment With Cephalexin for Lyme Disease
John Nowakowski, MD;
Donna McKenna, ANP;
Robert B. Nadelman, MD;
Denise Cooper, BS;
Susan Bittker, MS;
Diane Holmgren, RN;
Charles Pavia, PhD;
Russell C. Johnson, PhD;
Gary P. Wormser, MD
Arch Fam Med. 2000;9:563-567.
Context Lyme disease typically presents with a skin lesion called erythema migrans (EM), which though often distinctive in appearance may be confused with cellulitis. The first-generation cephalosporin, cephalexin monohydrate, is effective for treating bacterial cellulitis but has not been recommended or studied for treating Lyme disease because of poor in vitro activity.
Objective To describe the outcome of patients with EM who were treated with cephalexin.
Patients and Methods Patients presenting with EM to the Lyme Disease Diagnostic Center in Westchester, NY (May 1992-September 1997). A 2-mm punch biopsy specimen of the leading edge of the EM lesion and/or blood was cultured for Borrelia burgdorferi.
Results Eleven (2.8%) of 393 study patients had been initially treated with cephalexin prior to our evaluation; 9 (82%) were originally diagnosed with cellulitis. Cephalexin was administered for 8.6 days (range, 2-21 days) prior to presentation. All 11 patients had clinical evidence of disease progression, including 8 whose rash enlarged, 2 who developed seventh-nerve palsy (1 with new EM lesions), and 1 who developed new EM lesions. Borrelia burgdorferi grew in cultures from 5 patients despite a mean of 9.8 days of treatment with cephalexin (range, 5-21 days).
Conclusion Cephalexin should not be used to treat early Lyme disease and should be prescribed with caution during the summer months for patients believed to have cellulitis in locations where Lyme disease is endemic.
From the Division of Infectious Diseases (Drs Nowakowski, Nadelman, and Wormser and Ms McKenna, Ms Cooper, Ms Bittker, and Ms Holmgren), Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla; the Department of Microbiology (Dr Johnson), University of Minnesota, Minneapolis; and New York College of Osteopathic Medicine Microbiology Laboratory (Dr Pavia), New York Institute of Technology, Old Westbury.
RELATED ARTICLE
The Archives of Family Medicine Continuing Medical Education Program
Arch Fam Med. 2000;9(6):551-552.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Clinical practice. Early Lyme disease.
Wormser
NEJM 2006;354:2794-2801.
FULL TEXT
Diagnosis of Lyme Borreliosis
Aguero-Rosenfeld et al.
Clin. Microbiol. Rev. 2005;18:484-509.
ABSTRACT
| FULL TEXT
In Vitro Susceptibility Testing of Borrelia burgdorferi Sensu Lato Isolates Cultured from Patients with Erythema Migrans before and after Antimicrobial Chemotherapy
Hunfeld et al.
Antimicrob. Agents Chemother. 2005;49:1294-1301.
ABSTRACT
| FULL TEXT
Efficacy of Short-Course Ceftriaxone Therapy for Borrelia burgdorferi Infection in C3H Mice
Pavia et al.
Antimicrob. Agents Chemother. 2002;46:132-134.
ABSTRACT
| FULL TEXT
Lyme Disease
Steere
NEJM 2001;345:115-125.
FULL TEXT
Efficacy of an Evernimicin (SCH27899) In Vitro and in an Animal Model of Lyme Disease
Pavia et al.
Antimicrob. Agents Chemother. 2001;45:936-937.
ABSTRACT
| FULL TEXT
|
